Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
India
· Delayed Price · Currency is INR | Market Cap | 206.55B |
| Revenue (ttm) | 24.04B |
| Net Income (ttm) | 4.17B |
| Shares Out | 83.33M |
| EPS (ttm) | 50.01 |
| PE Ratio | 49.57 |
| Forward PE | 42.84 |
| Dividend | 18.00 (0.72%) |
| Ex-Dividend Date | Feb 5, 2025 |
| Volume | 87,652 |
| Average Volume | 199,101 |
| Open | 2,487.75 |
| Previous Close | 2,488.00 |
| Day's Range | 2,460.00 - 2,505.00 |
| 52-Week Range | 2,165.80 - 3,653.95 |
| Beta | 0.37 |
| RSI | 43.44 |
| Earnings Date | May 9, 2025 |
About Dr. Lal PathLabs
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India. [Read more]
Financial Performance
In 2023, Dr. Lal PathLabs's revenue was 22.27 billion, an increase of 10.40% compared to the previous year's 20.17 billion. Earnings were 3.58 billion, an increase of 49.78%.
Financial StatementsNews
Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls
Shares of Dr Lal Path Labs surged by 3.46%, rising ₹112.75 to trade at ₹3,368.45 on the NSE at 9:16 AM. The stock’s upward movement follows the release of strong Q2 FY25 earnings and positive brokerag...
Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying
Several brokerages have shared their views on Dr Lal Path Labs. Here’s what they are saying: Goldman Sachs: Goldman Sachs has maintained its sell call on Dr Lal Path and raised the share price target ...
UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price
UBS has maintained its buy rating on Dr LalPath Labs, with a share price target of ₹3,500, indicating a 7.7% upside from the current market price (CMP). The company’s Q2 performance was robust, showin...
Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore
Dr Lal PathLabs has reported solid financial results for Q2 FY25, showing notable growth in both revenue and net profit on a year-on-year (YoY) basis. Key Financial Highlights: Revenue for Q2 FY25 sto...
Nomura maintains ‘Buy’ on Dr Lal PathLabs, target price set at ₹3,720
Nomura has maintained its ‘Buy’ rating on Dr Lal PathLabs, setting a target price of ₹3,720, which implies a potential upside from the current market price of ₹3,280. Nomura expects steady performance...